Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae

Kenneth P Smith; James E Kirby

doi:10.1016/j.diagmicrobio.2016.09.002

Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae

Diagn Microbiol Infect Dis. 2016 Dec;86(4):439-441. doi: 10.1016/j.diagmicrobio.2016.09.002. Epub 2016 Sep 8.

Authors

Kenneth P Smith¹, James E Kirby²

Affiliations

¹ Department of Pathology, 330 Brookline Avenue - YA309, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: [email protected].
² Department of Pathology, 330 Brookline Avenue - YA309, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: [email protected].

PMID: 27745736
DOI: 10.1016/j.diagmicrobio.2016.09.002

Abstract

We evaluated activity of apramycin, a non-ototoxic/non-nephrotoxic aminocyclitol against 141 clinical Enterobacteriaceae isolates, 51% of which were non-susceptible to carbapenems (CRE). Among CRE, 70.8% were apramycin susceptible, which compared favorably to aminoglycosides in current clinical use. Our data suggest that apramycin deserves further investigation as a repurposed, anti-CRE therapeutic.

Keywords: Activity spectrum; Aminoglycoside; Apramycin; Carbapenem-resistant Enterobacteriaceae; Multidrug-resistance; Repurposing.

MeSH terms

Anti-Bacterial Agents / pharmacology*
Enterobacteriaceae / drug effects*
Enterobacteriaceae / isolation & purification
Enterobacteriaceae Infections / microbiology
Humans
Microbial Sensitivity Tests
Nebramycin / analogs & derivatives*
Nebramycin / pharmacology
beta-Lactam Resistance*

Substances

Anti-Bacterial Agents
Nebramycin
apramycin